Pliant Therapeutics (PLRX)
(Real Time Quote from BATS)
$13.48 USD
+0.03 (0.22%)
Updated Aug 26, 2024 01:16 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Pliant Therapeutics, Inc. (PLRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.00 | $47.00 | $32.00 | 204.83% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Pliant Therapeutics, Inc. comes to $41.00. The forecasts range from a low of $32.00 to a high of $47.00. The average price target represents an increase of 204.83% from the last closing price of $13.45.
Analyst Price Targets (12)
Broker Rating
Pliant Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 14.29%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PLRX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
8/8/2024 | Cantor Fitzgerald & Co | Pete Stavropoulos | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/7/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
7/18/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
7/16/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/5/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
3/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/7/2024 | Canaccord Genuity | Edward H Nash | Strong Buy | Strong Buy |
1/2/2024 | BTIG | Thomas Shrader | Not Available | Strong Buy |
12/8/2023 | Wells Fargo Securities | Tiago Fauth | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 14 |
Average Target Price | $41.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.98 |